VEA
ORIC icon

Virtus ETF Advisers’s Oric Pharmaceuticals ORIC Stock Holding History

Virtus ETF Advisers’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,434
Closed -$68.1K – 678
2024
Q4 		$68.1K Sell
8,434
-3,563
-30% -$32.7K 0.03% 395
2024
Q3 		$123K Buy
11,997
+210
+2% +$2.08K 0.06% 349
2024
Q2 		$83.3K Buy
11,787
+2,350
+25% +$21K 0.04% 389
2024
Q1 		$130K Sell
9,437
-648
-6% -$7.7K 0.07% 341
2023
Q4 		$92.8K Buy
+10,085
New +$72.9K 0.06% 392
2022
Q2 		– Sell
-12,914
Closed -$69K – 463
2022
Q1 		$69K Sell
12,914
-763
-6% -$6.87K 0.03% 353
2021
Q4 		$201K Buy
13,677
+2,895
+27% +$45.1K 0.08% 207
2021
Q3 		$225K Sell
10,782
-567
-5% -$11.5K 0.1% 240
2021
Q2 		$201K Buy
11,349
+2,955
+35% +$64.8K 0.08% 343
2021
Q1 		$206K Buy
8,394
+147
+2% +$4.64K 0.09% 324
2020
Q4 		$279K Buy
+8,247
New +$237K 0.12% 248

Other funds holding ORIC

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Virtus ETF Advisers's ORIC Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Oric Pharmaceuticals (ORIC) in Q1 2025, closing a stake of 8,434 shares — an estimated $68.1K sold.

Virtus ETF Advisers first reported a position in ORIC in Q4 2020 and held it in 11 quarters. The position peaked at $279K in Q4 2020. 143 funds tracked by Wall St. Rank hold ORIC as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Oric Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 8,434 Oric Pharmaceuticals shares in Q1 2025, an estimated $68.1K.
  • Virtus ETF Advisers first reported a position in Oric Pharmaceuticals in Q4 2020 and held it in 11 quarters.
  • Virtus ETF Advisers's Oric Pharmaceuticals position peaked at $279K in Q4 2020.
  • 143 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.